MAP2K1 and melanoma: Taken together, the in-vitro and in-vivo experiments indicated that co-targeting of MEK1/2 and PI3K/mTOR has improved anti-tumor activity compared to co-targeting of mutant BRAF and PI3K/mTOR even in melanoma cells with an intrinsic cross-resistant phenotype.